• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

August 1, 2011: Transmissible Spongiform Encephalopathies Advisory Committee Meeting Final Agenda

AGENDA

Transmissible Spongiform Encephalopathies Advisory Committee
24nd Meeting, August 1, 2011

The Hilton Washington DC North/Gaithersburg
620 Perry Parkway
Gaithersburg, MD 20877

Monday, August 1, 2011

9:00 am.Opening Remarks, Chair, TSEAC
Statement of Conflicts of Interest, Announcements
9:10 a.m.Topic I: Donor Deferral for Time Spent in Saudi Arabia to Reduce Risk of vCJD by Blood and Blood Products and Human Cells, Tissues and Cellular and Tissue-based Products (HCT/Ps)

 

  1. Introduction to the Topic and Background, David Asher, M.D., OBRR, FDA (35’)
  2. vCJD World Situation and Updates, Robert Will, M.D., CJD Surveillance Unit, Edinburgh (30’)
  3. Description of Recent vCJD Case and vCJD-related Blood Donor Policies in Canada: Michael B. Coulthart, Ph.D., Canadian CJD Surveillance System and Prion Diseases Program, Public Health Agency of Canada (30’)
10:45 a.m.Break (15’)
11:00 a.m.
  1. Description of Two vCJD Cases Attributed to Exposure to the BSE Agent in Saudi Arabia, Lawrence Schonberger, M.D., M.P.H., Centers for Disease Control (25’)
  2. U.S. vCJD Donor Evaluation for Geographic BSE Exposure
    1. Blood and Blood Components, Luisa Gregori, Ph.D., OBRR FDA (20’)
    2. ii. HCT/Ps, Melissa Greenwald, M.D., OCGTG, FDA (15’)
12:15 p.m.Lunch
1:15 p.m.
  1. Potential Effects of Additional Donor Deferrals on the Armed Services Blood Program, David A. Lincoln, Lt Col, USAF, BSC, Armed Services Blood Program (20’)
  2. Potential Effects of Additional Donor Deferrals on the U.S. Blood Supply, Hong Yang, Ph.D., OBE, FDA (20’)
  3. Summary and Questions for the Committee, Pedro Piccardo, M.D. (10’)
2:15 p.m.Break
2:30 p.m.Open Public Hearing
 There were no prior requests from the public to address the Committee at this time. You should ask if there is anyone in the audience who would like to address the committee.
If so, you will need to read an OPH Statement (in your folder or I will have one)
3:00 p.m.Open Committee Discussion

 

Questions for the Committee

4:30 p.m.Adjournment